In 2004, the U.S. Food & Drug Administration (FDA) approved BTA; (onabotulinumtoxinA) for excessive sweating of the underarms (axillary hyperhidrosis) in patients unable to obtain relief using antiperspirant.
Using local injections of BTA to alleviate the symptoms of hyperhidrosis is a promising approach.
Research has shown that treating excessive sweating of the armpits, hands, feet, and face with BTA is safe and effective. In one clinical study involving 322 patients with severe underarm sweating, 81% of the patients receiving BTA; injections achieved a greater than 50% reduction in sweating. And, 50% of the patients had their excessive sweating relieved for at least 201 days (nearly 7 months).
BTA; is a natural, purified protein with the ability to temporarily block the secretion of the chemical that is responsible for “turning on” the body’s sweat glands. By blocking, or interrupting, this chemical messenger, BTA; “turns off” sweating at the area where it has been injected.